Blood atherogenicity as a target for anti-atherosclerotic therapy

Current Pharmaceutical Design

Volumn 19, Issue 33, 2013, Pages 5954-5962

  Sobenin, Igor A ^a,b   Chistiakov, Dimitry A ^c   Bobryshev, Yuri V ^d,e   Orekhov, Alexander N ^b,d  

^a INSTITUTE OF EXPERIMENTAL CARDIOLOGY   (Russian Federation)

^b INSTITUTE OF GENERAL PATHOLOGY AND PATHOPHYSIOLOGY   (Russian Federation)

^c PIROGOV RUSSIAN NATIONAL RESEARCH MEDICAL UNIVERSITY   (Russian Federation)

^d Institute for Atherosclerosis Research   (Russian Federation)

^e UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

Antiatherosclerotic therapy; Atherogenesis; Atherogenicity; Atherosclerosis; Intracellular cholesterol accumulation

Indexed keywords

ALPRENOLOL; APOLIPOPROTEIN B100; APOLIPOPROTEIN C1; APOLIPOPROTEIN C2; APOLIPOPROTEIN C3; ATORVASTATIN; CHOLESTEROL ESTER; CHYLOMICRON; GELATINASE A; GELATINASE B; HIGH DENSITY LIPOPROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 10; INTERLEUKIN 6; INTERLEUKIN 8; INTERMEDIATE DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; METOPROLOL; MICRORNA 29; OXIDIZED LOW DENSITY LIPOPROTEIN; PLACEBO; PRAVASTATIN; PROPRANOLOL; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA; VERY LOW DENSITY LIPOPROTEIN;

ACUTE CORONARY SYNDROME; ANTIGEN ANTIBODY COMPLEX; ANTIGEN PRESENTING CELL; ANTIPROLIFERATIVE ACTIVITY; ARTERIAL WALL THICKNESS; ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CELL DIFFERENTIATION; CELL MATURATION; CELL MIGRATION; CELL PROLIFERATION; COMPLEMENT ACTIVATION; DENDRITIC CELL; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM CELL; GLYCATION; LIPID METABOLISM; LIPID PEROXIDATION; LIPID STORAGE; LIPOGENESIS; LOW DRUG DOSE; PLEIOTROPY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL (TOPIC);

ANIMALS; ATHEROSCLEROSIS; CELL CULTURE TECHNIQUES; CLINICAL TRIALS AS TOPIC; CORONARY ARTERY DISEASE; DRUG DISCOVERY; HUMANS; HYPOLIPIDEMIC AGENTS; LIPOPROTEINS; MODELS, BIOLOGICAL; MOLECULAR TARGETED THERAPY;

EID: 84878770286     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/1381612811319330014     Document Type: Article

References (123)

1. Chazov EI, Tertov VV, Orekhov AN, et al. Atherogenicity of blood serum from patients with coronary heart disease. Lancet 1986; 2: 595-8.
2. Orekhov AN, Tertov VV, Pokrovsky SN, et al. Blood serum atherogenicity associated with coronary atherosclerosis. Evidence for nonlipid factor providing atherogenicity of low-density lipoproteins and an approach to its elimination. Circ Res 1988; 62: 421-9.
3. Tertov VV, Orekhov AN, Martsenyuk ON, et al. Low-density lipoproteins isolated from the blood of patients with coronary heart disease induce the accumulation of lipids in human aortic cells. Exp Mol Pathol 1989; 50: 337-47.
4. Tertov VV, Orekhov AN, Sobenin IA, et al. Three types of naturally occurring modified lipoproteins induce intracellular lipid accumulation due to lipoprotein aggregation. Circ Res 1992; 71: 218-28.
5. Orekhov AN, Tertov VV, Kudryashov SA, et al. Trigger-like stimulation of cholesterol accumulation and DNA and extracellular matrix synthesis induced by atherogenic serum or low density lipoprotein in cultured cells. Circ Res 1990; 66: 311-20.
6. Biasucci LM, Biasillo G, Stefanelli A. Inflammatory markers, cholesterol and statins: pathophysiological role and clinical importance. Clin Chem Lab Med 2010; 48: 1685-91
7. Orekhov AN, Tertov VV, Kudryashov SA, et al. Primary culture of human aortic intimal cells as a model for testing antiatherosclerotic drugs. Effects of cyclic AMP, prostaglandins, calcium antagonists, antioxidants, and lipid-lowering agents. Atherosclerosis 1986; 60: 101-10.
8. Orekhov AN, Baldenkov GN, Tertov VV, et al. Cardiovascular drugs and atherosclerosis: effects of calcium antagonists, betablockers, and nitrates on atherosclerotic characteristics of human aortic cells. J Cardiovasc Pharmacol 1988; 12 Suppl 6: S66-8.
9. Orekhov AN. In vitro models of anti-atherosclerotic effects of cardiovascular drugs. Am J Cardiol 1990; 66: 23I-28I.
10. Orekhov AN, Baldenkov GN, Tertov VV, et al. Antiatherosclerotic effects of calcium antagonists. Study in human aortic cell culture. Herz 1990 15: 139-45.
11. Orekhov AN, Tertov VV, Lyakishev AA, Ruda MYa. Use of cultured atherosclerotic cells for investigation of antiatherosclerotic effects of anipamil and other calcium antagonists. J Hum Hypertens 1991; 5: 425-30.
12. Orekhov AN, Tertov VV, Pivovarova EM. The effects of antihypertensive agents on atherosclerosis-related parameters of human aorta intimal cells. Cardiology 1998; 89: 111-8.
13. Anitschkow N, Chalatow S. Ueber experimentelle Cholesterinsteatose und ihre Bedeutung fuer die Entstehung einiger pathologischer Prozesse. Zentrbl Allg Pathol Pathol Anat 1913; 24: 1-9.
14. Orekhov AN, Andreeva ER, Krushinsky AV, et al. Intimal cells and atherosclerosis. Relationship between the number of intimal cells and major manifestations of atherosclerosis in the human aorta. Am J Pathol 1986; 125: 402-15.
15. Finking G, Hanke H. Nikolaj Nikolajewitsch Anitschkow (1885-1964) established the cholesterol-fed rabbit as a model for atherosclerosis research. Atherosclerosis 1997; 135: 1-7.
16. Cho KH. Biomedicinal implications of high-density lipoprotein: its composition, structure, functions, and clinical applications. BMB Rep 2009; 42: 393-400.
17. Olofsson SO, Wiklund O, Borén J. Apolipoproteins A-I and B: biosynthesis, role in the development of atherosclerosis and targets for intervention against cardiovascular disease. Vasc Health Risk Manag 2007; 3: 491-502.
18. Davidson NO. Apolipoprotein B mRNA editing: a key controlling element targeting fats to proper tissue. Ann Med 1993; 25: 539-43.
19. Hatters DM, Peters-Libeu CA, Weisgraber KH. Apolipoprotein E structure: insights into function. Trends Biochem Soc 2006; 31: 445-54.
20. Ferri N, Paoletti R, Corsini A. Biomarkers for atherosclerosis: pathophysiological role and pharmacological modulation. Curr Opin Lipidol 2006; 17: 495-501.
21. Sharrett AR, Patsch W, Sorlie PD, et al. Associations of lipoprotein cholesterols, apolipoproteins A-I and B, and triglycerides with carotid atherosclerosis and coronary heart disease. The Atherosclerosis Risk in Communities (ARIC) Study. Arterioscler Thromb 1994; 14: 1098-104.
22. Millen BE, Franz MM, Quatromoni PA, et al. Diet and plasma lipids in women. I. Macronutrients and plasma total and lowdensity lipoprotein cholesterol in women: the Framingham nutrition studies. J Clin Epidemiol 1996; 49: 657-63.
23. Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 1998; 279: 1615-22.
24. Grundy SM, Cleeman JL, Mercz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. Circulation 2004; 110: 227-39.
25. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972; 18: 499-502.
26. van Deventer HE, Miller WG, Myers GL, et al. Non-HDL cholesterol shows improved accuracy for cardiovascular risk score classification compared to direct or calculated LDL cholesterol in a dyslipidemic population. Clin Chem 2011; 57: 490-501.
27. Blaha MJ, Blumenthal RS, Brinton EA, Jacobson TA. National Lipid Association Taskforce on Non-HDL Cholesterol. The importance of non-HDL cholesterol reporting in lipid management. J Clin Lipidol 2008; 2: 267-73.
28. Brunzell JD, Davidson M, Furberg CD, Lipoprotein management in patients with cardiometabolic risk: consensus conference report from the American Diabetes Association and the American College of Cardiology Foundation. J Am Coll Cardiol 2008; 51: 1512-24.
29. Levitan I, Volkov S, Subbaiah PV. Oxidized LDL: diversity, patterns of recognition, and pathophysiology. Antioxid Redox Signal 2010; 13: 39-75.
30. Miller YI, Choi SH, Fang L, Tsimikas S. Lipoprotein modification and macrophage uptake: role of pathologic cholesterol transport in atherogenesis. Subcell Biochem 2010; 51: 229-51.
31. Soran H, Durrington PN. Susceptibility of LDL and its subfractions to glycation. Curr Opin Lipidol 2011; 22: 254-61.
32. Fogelstrand B, Borén J. Retention of atherogenic lipoproteins in the artery wall and its role in atherogenesis. Nutr Metab Cardiovasc Dis 2012; 22: 1-7.
33. Yan M, Mehta JL, Hu C. LOX-1 and obesity. Cardiovasc Drugs Ther 2011; 25: 469-76.
34. Mitra S, Goyal T, Mehta JL. Oxidized LDL, LOX-1 and atherosclerosis. Cardiovasc Drugs Ther 2011; 25: 419-29.
35. Han CY, Park SY, Pak YK. Role of endocytosis in the transactivation of nuclear factor-kappaB by oxidized low-density lipoprotein. Biochem J 2000; 350 Pt 3: 829-37.
36. Monaco C, Andreakos E, Kiriakidis S, et al. Canonical pathway of nuclear factor kappa B activation selectively regulates proinflammatory and prothrombotic responses in human atherosclerosis. Proc Natl Acad Sci USA 2004; 101: 5634-9.
37. Nickel T, Schmauss D, Hanssen H, et al. OxLDL uptake by dendritic cells induces upregulation of scavenger-receptors, maturation and differentiation. Atherosclerosis 2009; 205: 442-50.
38. Tertov VV, Orekhov AN, Sayadyan KS, et al. Correlation between cholesterol content in circulating immune complexes and atherogenic properties of CHD patients' serum manifested in cell culture. Atherosclerosis 1990; 81: 183-9.
39. Orekhov AN, Tertov VV, Kabakov AE, et al. Autoantibodies against modified low density lipoprotein. Nonlipid factor of blood plasma that stimulates foam cell formation. Arterioscler Thromb 1991; 11: 316-26.
40. Bobryshev YV, Andreeva ER, Mikhailova IA, et al. Correlation between lipid deposition, immune-inflammatory cell content and MHC class II expression in diffuse intimal thickening of the human aorta. Atherosclerosis 2011; 219: 171-83.
41. Sobenin IA, Karagodin VP, Melnichenko AA, et al. Diagnostic and prognostic value of low density lipoprotein-containing circulating immune complexes in atherosclerosis. J Clin Immunol 2012; doi: 10.1007/s10875-012-9819-4.
42. Sobenin IA, Orekhova VA, Melnichenko AA, et al. Low density lipoprotein-containing circulating immune complexes have better prognostic value in carotid intima-media thickness progression than other lipid parameters. Int J Cardiol 2012; doi: 10.1016/j.ijcard.2012.09.175.
43. Burut DF, Karim Y, Ferns GA. The role of immune complexes in atherogenesis. Angiology 2010; 61: 679-89.
44. Goettsch C, Rauner M, Hamann C, et al. Nuclear factor of activated T cells mediates oxidized LDL-induced calcification of vascular smooth muscle cells. Diabetologia 2011; 54: 2690-701.
45. Li HX, Kong FJ, Bai SZ, et al. Involvement of calcium-sensing receptor in oxLDL-induced MMP-2 production in vascular smooth muscle cells via PI3K/Akt pathway. Mol Cell Biochem 2012; 362: 115-22.
46. Chen KC, Wang YS, Hu CY, et al. OxLDL up-regulates microRNA-29b, leading to epigenetic modifications of MMP-2/MMP-9 genes: a novel mechanism for cardiovascular diseases. FASEB J 2011; 25: 1718-28.
47. Younis NN, Soran H, Pemberton P, et al. Small dense LDL is more susceptible to glycation than more buoyant LDL in Type 2 diabetes. Clin Sci (Lond) 2013 124: 343-9.
48. Reaven PD, Grasse BJ, Tribble DL. Effects of linoleate-enriched and oleate-enriched diets in combination with alpha-tocopherol on the susceptibility of LDL and LDL subfractions to oxidative modification in humans. Artherioscler Thromb 1994; 14: 557-66.
49. Sevanian A, Hwang J, Hodis H, et al. Contribution of an in vivo oxidized LDL to LDL oxidation and its association wth dense LDL subpopulations. Artherioscler Thromb Vasc Biol 1996; 16: 784-93.
50. Teramoto T, Watanabe T, Matsushima T, Horie Y, Oka H. Characterization of nascent lipoproteins produced by perfused rat liver: evidence of hepatic secretion and post-secretory modification of nascent lipoproteins. J Biochem. 1990; 107(4):519-25.
51. Skålén K, Gustafsson M, Rydberg EK, et al. Subendothelial retention of atherogenic lipoproteins in early atherosclerosis. Nature 2002; 417: 750-4.
52. Goldberg IJ, Wagner WD, Pang L, et al. The NH2-terminal region of apolipoprotein B is sufficient for lipoprotein association with glycosaminoglycans. J Biol Chem 1998; 273:35355-61.
53. Gustaggson B, Borén J. Mechanism of lipoprotein retention by the extracellular matrix. Curr Opin Lipidol 2004; 15: 505-14.
54. Talmud PJ, Hawe E, Miller GJ, Humphries SE. Nonfasting apolipoprotein B and triglyceride levels as a useful predictor of coronary heart disease risk in middle-aged UK men. Arherioscler Thromb Vasc Biol 2002; 22: 1918-23.
55. Cromwell WC, Otvos JD, Keyes MJ, et al. LDL particle number and risk of future cardiovascular disease in the Framingham Offspring Study-Implications for LDL management. J Clin Lipidol 2007; 1: 583-92.
56. Holme I, Aastveit AH, Hammar N, et al. Inflammatory markers, lipoprotein components and risk of major cardiovascular events in 65, 005 men and women in the Apolipoprotein MOrtality RISk study (AMORIS). 2010; 213: 299-305.
57. Walldius G, Jungner I, Holme I, et al. High apolipoprotein B, low apolipoprotein A-1, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study. Lancet 2001; 358: 2026-33.
58. Walldius G, Jungner I, Aastveit AH, et al. The apoB/apoA-I ratio is better than the cholesterol ratios to estimate the balance between plasma proatherogenic and antiatherogenic lipoproteins and to predict coronary risk. Clin Chem Lab Med 2004; 42: 1355-63.
59. Walldius G, Jungner I. The apoB/apoA-I ratio: a strong, new risk factor for cardiovascular disease and a target for lipid-lowering therapy-a review of the evidence. J Intern Med 2006; 259: 493-519.
60. Sniderman AD, Holme I, Aastveit A, et al. Relation of age, the apolipoprotein B/apolipoprotein A-I ratio, and the risk of fatal myocardial infarction and implications for the primary prevention of cardiovascular disease. Am J Cardiol 2007; 100: 217-21.
61. Marcovina SM, Albers JJ, Kennedy H, et al. International Federation of Clinical Chemistry standardization project for measurements of apolipoproteins A-1 and B. IV. Comparability of apolipoprotein B values by use of International Reference Material. Clin Chem 1994; 40: 586-92.
62. Marcovina SM, Albers JJ, Henderson LO, Hannon WH. International Federation of Clinical Chemistry standardization project for measurements of apolipoproteins A-I and B. III. Comparability of apolipoprotein A-I values by use of international reference material. Clin Chem 1993; 39: 773-81.
63. Charlton-Menys V, Fuller J, France M, et al. Apolipoproteins, cardiovascular risk and statin response in type 2 diabetes: the Collaborative Atorvastatin Diabetes Study (CARDS). Diabetologia 2009; 52: 218-25.
64. Ray KK, Cannon CP, Cairns R, et al. Prognostic utility of apoB/A1, total cholesterol/HDL, non-HDL cholesterol, or hs-CRP as predictors of clinical risk in patients receiving statin therapy after acute coronary syndromes: results from PROVE IT-TIMI 22. Arterioscler Thromb Vasc Biol 2009; 29: 424-30.
65. Veerkamp MJ, de Graaf J, Hendriks JC, et al. Nomogram to diagnose familial combined hyperlipidemia on the basis of results of a 5-year follow-up study. Circulation 2004; 109: 2980-5.
66. Song C, Hsu K, Yamen E, et al. Serum amyloid A induction of cytokines in monocytes/macrophages and lymphocytes. Atherosclerosis 2009; 207: 374-83.
67. Ray BK, Chatterjee S, Ray A. Mechanism of minimally modified LDL-mediated induction of serum amyloid A gene in monocyte/ macrophage cells. DNA Cell Biol 1999; 18: 65-73.
68. Singh U, Dasu MR, Yancey PG, et al. Human C-reactive protein promotes oxidized low density lipoprotein uptake and matrix metalloproteinase-9 release in Wistar rats. J Lipid Res 2008; 49: 1015-23.
69. Venugopal SK, Devaraj S, Jialal I. Effect of C-reactive protein on vascular cells: evidence for a proinflammatory, proatherogenic role. Curr Opin Nephrol Hypertens 2005; 14: 33-7.
70. Devaraj S, Jialal I. C-reactive protein polarizes human macrophages to an M1 phenotype and inhibits transformation to the M2 phenotype. Artherioscleros Thromb Vasc Biol 2011; 31: 1397-402.
71. Devaraj S, Kumaresan PR, Jialal I. Effect of C-reactive protein on chemokine expression in human aortic endothelial cells. J Mol Cell Cardiol 2004; 36: 405-10.
72. Devaraj S, Yun JM, Duncan-Staley C, Jialal I. C-reactive protein induces M-CSF release and macrophage proliferation. J Leukoc Biol 2009; 85: 262-7.
73. Kleemann R, Zadelaar S, Kooistra T. Cytokines and atherosclerosis: a comprehensive review of studies in mice. Cardiovasc Res 2008; 79: 360-76.
74. Butcher M, Galkina E. Current views on the functions of interleukin-17A-producing cells in atherosclerosis. Thromb Haemost 2011; 106: 787-95.
75. McLaren JE, Michael DR, Ashlin TG, Ramji DP. Cytokines, macrophage lipid metabolism and foam cells: implications for cardiovascular disease therapy. Prog Lipid Res 2011; 50: 331-47.
76. Ruijanto A. The role of vascular smooth muscle cells on the pathogenesis of atherosclerosis. Acta Med Indones 2007; 39: 86-93.
77. Kleinbongard P, Heusch G, Schulz R. TNF-alpha in atherosclerosis, myocardial ischemia/reperfusion and heart failure. Pharmacol Ther 2010; 127: 295-314.
78. Loppnow H, Buerke M, Werdan K, Rose-John S. Contribution of vascular cell-derived cytokines to innate and inflammatory pathways in atherogenesis. J Cell Mol Med 2011; 15: 484-500.
79. Zhao G, Xu MJ, Zhao MM, et al. Activation of nuclear factorkappa B accelerates vascular calcification by inhibiting ankylosis protein homolog expression. Kidney Int 2012; 82: 34-44.
80. Escobales N. Testing of anti-atherogenic drugs and food components on cell cultures: assessment of reliability. Author's reply. P R Health Sci J 2010; 29:87.
81. Badimon L, Vilahur G, Padro T. Nutraceuticals and atherosclerosis: human trials. Cardiovasc Ther 2010; 28: 202-15.
82. Tomasoni L, Sitia S, Borghi C, et al. Effects of treatment strategy on endothelial function. Autoimmun Rev 2010; 9: 840-4.
83. Orekhov AN, Tertov VV, Sobenin IA, Pivovarova EM. Direct antiatherosclerosis-related effects of garlic. Ann Med 1995 27: 63-5.
84. Orekhov AN, Grunwald J. Effects of garlic on atherosclerosis. Nutrition 1997; 13: 656-63.
85. Orekhov AN, Tertov VV. In vitro effect of garlic powder extract on lipid content in normal and atherosclerotic human aortic cells. Lipids 1997; 32: 1055-60.
86. Sobenin IA, Andrianova IV, Demidova ON, et al. Lipid-lowering effects of time-released garlic powder tablets in double-blinded placebo-controlled randomized study. J Atheroscler Thromb 2008; 15: 334-8.
87. Sobenin IA, Nedosugova LV, Filatova LV, et al. Metabolic effects of time-released garlic powder tablets in type 2 diabetes mellitus: the results of double-blinded placebo-controlled study. Acta Diabetol 2008; 45: 1-6.
88. Sobenin IA, Andrianova IV, Fomchenkov IV, et al. Time-released garlic powder tablets lower systolic and diastolic blood pressure in men with mild and moderate arterial hypertension. Hypertens Res 2009; 32:433-7.
89. Sobenin IA, Andrianova IV, Ionova V, et al. Anti-aggregatory and fibrinolytic effects of time-released garlic powder tablets. 147. Appl Technol Innov 2012; 7: 40-5.
90. Sobenin IA, Pryanishnikov VV, Kunnova LM, et al. The effects of time-released garlic powder tablets on multifunctional cardiovascular risk in patients with coronary artery disease. Lipids Health Dis 2010; 9: 119.
91. Rahman K, Lowe GM. Garlic and cardiovascular disease: a critical review. J Nutr 2006; 136 (3 Suppl): 736S-40S.
92. Orekhov AN, Sobenin IA, Korneev NV, et al. Anti-atherosclerotic therapy based on botanicals. Recent Pat Cardiovasc Drug Discov 2012 Nov 23. [Epub ahead of print].
93. Orekhov AN, Andrianova IV, Rekhter MD., et al. Beta-blockers: propranolol, metoprolol, atenolol, pindolol, alprenolol and timolol, manifest atherogenicity on in vitro, ex vivo and in vivo models. Elimination of propranolol atherogenic effects by papaverine. Atherosclerosis 1992; 95: 77-85.
94. Orekhov AN, Ruda MY, Baldenkov GN, et al. Atherogenic effects of beta blockers on cells cultured from normal and atherosclerotic aorta. Am J Cardiol 1988; 61: 1116-7.
95. Sung JY, Choi HC. Nifedipine inhibits vascular smooth muscle cell proliferation and reactive oxygen species production through AMPactivated protein kinase signaling pathway. Vascul Pharmacol 2012; 56: 1-8.
96. Du M, Shen QW, Zhu MJ. Role of beta-adrenoceptor signaling and AMP-activated protein kinase in glycolysis of postmortem skeletal muscle. J Agric Food Chem 2005; 53: 3235-9.
97. Hayashi T, Hirshman MF, Kurth EJ, et al. Evidence for 5' AMPactivated protein kinase mediation of the effect of muscle contraction on glucose transport. Diabetes 1998; 47: 1369-73.
98. Ruderman NB, Park H, Kaushik VK, et al. AMPK as a metabolic switch in rat muscle, liver and adipose tissue after exercise. Acta Physiol Scand 2003; 178: 435-42.
99. Hattori A, Mawatari K, Tsuzuki S, et al. Beta-adrenergic-AMPK pathway phosphorylates acetyl-CoA carboxylase in a highepinephrine rat model, SPORTS. Obesity (Silver Spring) 2010; 18: 48-54.
100. Sobenin IA, Maksumova MA, Slavina ES, et al. Sulfonylureas induce cholesterol accumulation in cultured human intimal cells and macrophages. Atherosclerosis 1994; 105: 159-63.
101. Ong DS, Anzinger JJ, Leyva FJ, et al. Extracellular cholesterol-rich microdomains generated by human macrophages and their potential function in reverse cholesterol transport. J Lipid Res 2010; 51: 2303-13.
102. Rödler S, Roth M, Nauck M, et al. Ca(2+)-channel blockers modulate the expression of interleukin-6 and interleukin-8 genes in human vascular smooth muscle cells. J Mol Cell Cardiol 1995; 27: 2295-302.
103. Eickelberg O, Roth M, Block LH. Effects of amlodipine on gene expression and extracellular matrix formation in human vascular smooth muscle cells and fibroblasts: implications for vascular protection. Int J Cardiol 1997; 62 Suppl 2: S31-7.
104. Ikeda U, Shimpo M, Ohki R, et al. Amlodipine increases nitric oxide synthesis in cytokine-stimulated cultured vascualar smooth muscle cells. J Hypertens 2000; 18: 1597-604.
105. Lai YM, Fukuda N, Su JZ, et al. Novel mechanisms of the antiproliferative effects of amlodipine in vascular smooth muscle cells from spontaneously hypertensive rats. Hypertens Res 2002; 25: 109-15.
106. Smilde TJ, van Wissen S, Wollersheim H, et al. Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolaemia (ASAP): a prospective, randomised, double-blind trial. Lancet 2001; 357: 577-81.
107. Hodis HN. Reversibility of atherosclerosis-evolving perspectives from two arterial imaging clinical trials: the cholesterol lowering atherosclerosis regression study and the monitored atherosclerosis regression study. J Cardiovasc Pharmacol 1995; 25 Suppl 4: S25-31.
108. Blankenhorn DH, Azen SP, Kramsch DM, et al. Coronary angiographic changes with lovastatin therapy. The Monitored Atherosclerosis Regression Study (MARS). Ann Intern Med 1993; 119: 969-76.
109. Blankenhorn DH, Selzer RH, Crawford DW, et al. Beneficial effects of colestipol-niacin therapy on the common carotid artery. Two-and four-year reduction of intima-media thickness measured by ultrasound. Circulation 1993; 88: 20-8.
110. Pitt B, Byington RP, Furberg CD, et al. Effect of amlodipine on the progression of atherosclerosis and the occurrence of clinical events. PREVENT Investigators. Circulation 2000; 102: 1503-10.
111. Zanchetti A, Rosei EA, Dal P, et al. The Verapamil in Hypertension and Atherosclerosis Study (VHAS): results of long-term randomized treatment with either verapamil or chlorthalidone on carotid intima-media thickness. J Hypertens 1998; 16: 1667-76.
112. Tertov VV, Sobenin IA, Gabbasov ZA, et al. Three types of naturally occurring modified lipoproteins induce intracellular lipid accumulation in human aortic intimal cells-the role of lipoprotein aggregation. Eur J Clin Chem Clin Biochem 1992; 30: 171-8.
113. Tertov VV, Bittolo-Bon G, Sobenin IA, et al. Naturally occurring modified low density lipoproteins are similar if not identical: more electronegative and desialylated lipoprotein subfractions. Exp Mol Pathol 1995; 62: 166-72.
114. Tertov VV, Orekhov AN. Effect of lipoprotein(a) on lipid metabolism of cultured human intimal aortic cells. Chem Phys Lipids 1994; 67-68: 161-6.
115. Tertov VV, Sobenin IA, Gabbasov ZA, et al. Three types of naturally occurring modified lipoproteins induce intracellular lipid accumulation due to lipoprotein aggregation. Circ Res 1992; 71: 218-28.
116. Tertov VV, Sobenin IA, Orekhov AN. Similarity between naturally occurring modified desialylated, electronegative and aortic low density lipoprotein. Free Radic Res 1996; 25: 313-9.
117. Tertov VV, Kaplun VV, Sobenin IA, et al. Human plasma transsialidase causes atherogenic modification of low density lipoprotein. Atherosclerosis 2001; 159:103-15.
118. Tertov VV, Kaplun VV, Sobenin IA, Orekhov AN. Low-density lipoprotein modification occurring in human plasma possible mechanism of in vivo lipoprotein desialylation as a primary step of atherogenic modification. Atherosclerosis 1998; 138: 183-95.
119. Tertov VV, Sobenin IA, Kaplun VV, Orekhov AN. Antioxidant content in low density lipoprotein and lipoprotein oxidation in vivo and in vitro. Free Radic Res 1998; 29:165-73.
120. Tertov VV, Orekhov AN. Metabolism of native and naturally occurring multiple modified low density lipoprotein in smooth muscle cells of human aortic intima. Exp Mol Pathol 1997; 64: 127-45.
121. Sobenin IA, Suprun IV, Karagodin VP, et al. The interaction of plasma sialylated and desialylated lipoproteins with collagen from the intima and media of uninvolved and atherosclerotic human aorta. J Lipids 2011; 2011: 254267.
122. Tertov VV, Sobenin IA, Orekhov AN, et al. Characteristics of low density lipoprotein isolated from circulating immune complexes. Atherosclerosis 1996; 122: 191-9.
123. Orekhov AN, Kalenich OS, Tertov VV, et al. Diagnostic value of immune cholesterol as a marker for atherosclerosis. J Cardiovasc Risk 1995; 2: 459-66.